NEUPHORIA THERAPEUTICS INC (NEUP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:NEUP • US64136E1029

4.01 USD
+0.01 (+0.38%)
Last: Feb 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, NEUP scores 3 out of 10 in our fundamental rating. NEUP was compared to 524 industry peers in the Biotechnology industry. NEUP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEUP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NEUP had negative earnings in the past year.
  • In the past year NEUP had a positive cash flow from operations.
  • NEUP had negative earnings in each of the past 5 years.
  • NEUP had negative operating cash flow in 4 of the past 5 years.
NEUP Yearly Net Income VS EBIT VS OCF VS FCFNEUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of NEUP (-1.29%) is better than 87.98% of its industry peers.
  • The Return On Equity of NEUP (-1.95%) is better than 89.50% of its industry peers.
Industry RankSector Rank
ROA -1.29%
ROE -1.95%
ROIC N/A
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUP Yearly ROA, ROE, ROICNEUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • NEUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUP Yearly Profit, Operating, Gross MarginsNEUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NEUP has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NEUP has been reduced compared to 5 years ago.
  • The debt/assets ratio for NEUP has been reduced compared to a year ago.
NEUP Yearly Shares OutstandingNEUP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NEUP Yearly Total Debt VS Total AssetsNEUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -6.52, we must say that NEUP is in the distress zone and has some risk of bankruptcy.
  • NEUP has a Altman-Z score of -6.52. This is in the lower half of the industry: NEUP underperforms 63.74% of its industry peers.
  • NEUP has a debt to FCF ratio of 0.43. This is a very positive value and a sign of high solvency as it would only need 0.43 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.43, NEUP belongs to the best of the industry, outperforming 95.23% of the companies in the same industry.
  • NEUP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • NEUP has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.43
Altman-Z -6.52
ROIC/WACCN/A
WACC8.91%
NEUP Yearly LT Debt VS Equity VS FCFNEUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

2.3 Liquidity

  • A Current Ratio of 3.56 indicates that NEUP has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.56, NEUP is in line with its industry, outperforming 42.37% of the companies in the same industry.
  • A Quick Ratio of 3.56 indicates that NEUP has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.56, NEUP perfoms like the industry average, outperforming 44.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.56
NEUP Yearly Current Assets VS Current LiabilitesNEUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • NEUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.00%.
  • NEUP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.98% yearly.
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-33.45%
Revenue growth 5Y-59.98%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -186.38% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 14.87% on average over the next years. This is quite good.
EPS Next Y-104017.17%
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
EPS Next 5Y-186.38%
Revenue Next Year686792%
Revenue Next 2Y4405.1%
Revenue Next 3Y2711.32%
Revenue Next 5Y14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NEUP Yearly Revenue VS EstimatesNEUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2030 2031 2032 2033 0 100M 200M 300M
NEUP Yearly EPS VS EstimatesNEUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NEUP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NEUP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUP Price Earnings VS Forward Price EarningsNEUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150 -200

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, NEUP is valued cheaply inside the industry as 90.65% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 279.45
EV/EBITDA N/A
NEUP Per share dataNEUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NEUP's earnings are expected to grow with 165.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NEUP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUPHORIA THERAPEUTICS INC

NASDAQ:NEUP (2/6/2026, 8:00:01 PM)

4.01

+0.01 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)02-12
Inst Owners25.3%
Inst Owner Change13.3%
Ins Owners3.42%
Ins Owner ChangeN/A
Market Cap21.57M
Revenue(TTM)191.00K
Net Income(TTM)-370.00K
Analysts80
Price Target9.96 (148.38%)
Short Float %0.82%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-49.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-35.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.38
P/FCF 279.45
P/OCF 279.45
P/B 1.14
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-25.46
Fwd EYN/A
FCF(TTM)0.01
FCFY0.36%
OCF(TTM)0.01
OCFY0.36%
SpS2.91
BVpS3.53
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.29%
ROE -1.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 0.49%
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.43
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.56
Quick Ratio 3.56
Altman-Z -6.52
F-Score7
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-104017.17%
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
EPS Next 5Y-186.38%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-33.45%
Revenue growth 5Y-59.98%
Sales Q2Q%N/A
Revenue Next Year686792%
Revenue Next 2Y4405.1%
Revenue Next 3Y2711.32%
Revenue Next 5Y14.87%
EBIT growth 1Y93.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-238.53%
EBIT Next 3Y-65.01%
EBIT Next 5YN/A
FCF growth 1Y100.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.53%
OCF growth 3YN/A
OCF growth 5YN/A

NEUPHORIA THERAPEUTICS INC / NEUP FAQ

What is the fundamental rating for NEUP stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEUP.


What is the valuation status of NEUPHORIA THERAPEUTICS INC (NEUP) stock?

ChartMill assigns a valuation rating of 2 / 10 to NEUPHORIA THERAPEUTICS INC (NEUP). This can be considered as Overvalued.


Can you provide the profitability details for NEUPHORIA THERAPEUTICS INC?

NEUPHORIA THERAPEUTICS INC (NEUP) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for NEUP stock?

The Earnings per Share (EPS) of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -104017.17% in the next year.